If this box remains here for more than 30 seconds, click this link to try again.
Industries
Functions
Home » Products & Services » Best Practice Database » Quality, Compliance and Regulatory » Government Affairs and Public Policy
Download FREE Excerpt
10 Info Graphics
23 Data Graphics
150+ Metrics
3 Narratives
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Buy Now
STUDY OVERVIEW
The Government Affairs and Public Policy functions play a vital and growing role in the biopharma sector given the increasing importance that reimbursement, regulatory and political issues play in an organization's overall success in the marketplace. Thus, it is essential for these groups to have resourcing and funding levels that enable effective and efficient operations. Likewise, effective Government Affairs and Public Policy groups have clearly established service levels, priorities, and responsibilities. Best Practices, LLC undertook this study to identify the benchmarks of leading companies regarding the staffing, budgeting, service levels, and responsibilities of their Government Affairs and Public Policy groups. KEY TOPICS
Participants ranging from middle level management to senior executives at 15 leading bio-pharmaceutical, healthcare and medical device companies participated in the study. Field interviews and study analysis produced many observations and benchmark findings to reflect opportunities across the Public policy and Government Affairs function for organization growth and profitability.
Industries Profiled: Pharmaceutical; Health Care; Biotech; Chemical; Medical Device Companies Profiled: Boehringer Ingelheim; Novo Nordisk; Abbott Laboratories; Genentech; AstraZeneca; Roche; UCB Pharma; GlaxoSmithKline; Solvay Pharmaceuticals; Stiefel; Pfizer; Lilly; Baxter International; Cephalon; Inc.; DRI; Biomarin
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.
Top